Novavax Reports Fourth Quarter and Full Year 2023 Financial

Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza...

Related Keywords

Canada , Australia , Taiwan , India , New Zealand , Israel , France , Italy , Spain , Singapore , Johnc Jacobs , Ali Chartan , Erika Schultz , Leverage Technology Platform , Serum Institute Of India Pvt , University Of Oxford , Pharma Services , Linkedin , World Health Organization , Uk Health Security Agency , Nasdaq , Drug Administration , Exchange Commission , Vaccine Alliance Gavi , Serum Life Sciences , Serum Institute Of India , Novavax Inc , Influenza Combination , Chief Executive Officer , Emergency Use Authorization , Purchase Agreement , Green Book , Reduce Rate , Manage Cash Flow , Evolve Scale , Vaccine Alliance , Drive Additional Value Beyond Nuvaxovid , United Nation , Full Year , Serum Institute , Serum Life Sciences Limited , Financial Condition , Annual Report , Novavax , Nc ,